Theravance Biopharma (NASDAQ:TBPH) Given New $10.00 Price Target at Morgan Stanley

Theravance Biopharma (NASDAQ:TBPH) had its target price lowered by Morgan Stanley from $14.00 to $10.00 in a research note issued to investors on Thursday morning, Analyst Price Targets reports. The brokerage currently has an underweight rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently commented on the company. Robert W. Baird dropped their price objective on Theravance Biopharma from $10.00 to $7.00 and set a neutral rating on the stock in a research report on Thursday. Cowen lowered their target price on Theravance Biopharma from $14.00 to $8.00 and set a market perform rating on the stock in a report on Wednesday. Citigroup lowered their target price on Theravance Biopharma from $20.00 to $14.00 and set an underperform rating on the stock in a report on Tuesday, August 24th. JPMorgan Chase & Co. downgraded Theravance Biopharma from an overweight rating to an underweight rating and set a $7.00 target price on the stock. in a report on Wednesday. Finally, Needham & Company LLC downgraded Theravance Biopharma from a buy rating to a hold rating in a report on Wednesday. Four equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of Hold and an average price target of $12.70.

NASDAQ TBPH opened at $6.86 on Thursday. Theravance Biopharma has a 12 month low of $6.10 and a 12 month high of $22.74. The stock has a market cap of $504.00 million, a P/E ratio of -1.67 and a beta of 0.82. The stock’s fifty day moving average price is $11.63 and its 200-day moving average price is $16.30.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Monday, August 2nd. The biopharmaceutical company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.22. The business had revenue of $12.91 million for the quarter, compared to analysts’ expectations of $15.02 million. As a group, equities research analysts expect that Theravance Biopharma will post -3.6 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the stock. Newbridge Financial Services Group Inc. purchased a new stake in shares of Theravance Biopharma during the second quarter worth about $29,000. SG Americas Securities LLC purchased a new stake in shares of Theravance Biopharma during the second quarter worth about $117,000. HRT Financial LP purchased a new stake in shares of Theravance Biopharma during the first quarter worth about $200,000. Citigroup Inc. grew its position in shares of Theravance Biopharma by 57.7% during the second quarter. Citigroup Inc. now owns 9,905 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 3,626 shares in the last quarter. Finally, Handelsbanken Fonder AB purchased a new stake in shares of Theravance Biopharma during the second quarter worth about $196,000. Hedge funds and other institutional investors own 82.11% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

Further Reading: What is the definition of market timing?

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.